ML19211C127

From kanterella
Revision as of 12:05, 19 October 2019 by StriderTol (talk | contribs) (Created page by program invented by StriderTol)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Shine Medical Technologies, LLC, Final Safety Analysis Report, Chapter 16, Other License Considerations
ML19211C127
Person / Time
Site: SHINE Medical Technologies
Issue date: 07/17/2019
From:
SHINE Medical Technologies
To:
Office of Nuclear Reactor Regulation
References
2019-SMT-0054
Download: ML19211C127 (6)


Text

Chapter 16 - Other License Considerations Table of Contents CHAPTER 16 OTHER LICENSE CONSIDERATIONS TABLE OF CONTENTS Section Title Page 16.1 PRIOR USE OF FACILITY COMPONENTS ....................................................... 16.1-1 16.2 MEDICAL USE OF THE FACILITY ..................................................................... 16.2-1 SHINE Medical Technologies 16-i Rev. 0

Chapter 16 - Other License Considerations List of Tables LIST OF TABLES Number Title None SHINE Medical Technologies 16-ii Rev. 0

Chapter 16 - Other License Considerations List of Figures LIST OF FIGURES Number Title None SHINE Medical Technologies 16-iii Rev. 0

Chapter 16 - Other License Considerations Acronyms and Abbreviations ACRONYMS AND ABBREVIATIONS Acronym/Abbreviation Definition None SHINE Medical Technologies 16-iY Rev. 0

Chapter 16 - Other License Considerations Prior Use of Facility Components CHAPTER 16 - OTHER LICENSE CONSIDERATIONS 16.1 PRIOR USE OF FACILITY COMPONENTS The SHINE facility utilizes new and appropriately-qualified components and systems to conduct production operations. Discussions regarding used components and systems are not applicable to the SHINE facility.

SHINE Medical Technologies 16.1-1 Rev. 0

Chapter 16 - Other License Considerations Medical Use of the Facility 16.2 MEDICAL USE OF THE FACILITY The SHINE facility does not contain equipment or facilities associated with direct medical administration of radioisotopes or other radiation-based therapies. Therefore, discussions involving medical use of the SHINE facility are not applicable.

SHINE Medical Technologies 16.2-1 Rev. 0